Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 225

Similar articles for PubMed (Select 23247938)

1.

Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.

Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, Prens EP, Schlessinger J, Zouboulis CC, van der Zee HH, Rosenfeld M, Mulani P, Gu Y, Paulson S, Okun M, Jemec GB.

Ann Intern Med. 2012 Dec 18;157(12):846-55. doi: 10.7326/0003-4819-157-12-201212180-00004.

PMID:
23247938
2.

Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study.

Leonardi C, Sobell JM, Crowley JJ, Mrowietz U, Bao Y, Mulani PM, Gu Y, Okun MM.

Br J Dermatol. 2012 Sep;167(3):658-67. doi: 10.1111/j.1365-2133.2012.11041.x. Epub 2012 Aug 20.

PMID:
22564148
3.

Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.

Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM.

Am J Gastroenterol. 2009 May;104(5):1170-9. doi: 10.1038/ajg.2009.59. Epub 2009 Apr 7.

PMID:
19352339
4.

A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.

Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GB.

Br J Dermatol. 2011 Aug;165(2):391-8. doi: 10.1111/j.1365-2133.2011.10339.x. Epub 2011 Jun 30.

PMID:
21457202
5.

Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.

Sandborn WJ, Colombel JF, D'Haens G, Plevy SE, Panés J, Robinson AM, Pollack PF, Zhou Q, Castillo M, Thakkar RB.

Curr Med Res Opin. 2013 May;29(5):483-93. doi: 10.1185/03007995.2013.779575. Epub 2013 Mar 14.

PMID:
23438483
6.

Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study.

Asahina A, Nakagawa H, Etoh T, Ohtsuki M; Adalimumab M04-688 Study Group.

J Dermatol. 2010 Apr;37(4):299-310. doi: 10.1111/j.1346-8138.2009.00748.x.

PMID:
20507398
7.

Summaries for patients. Adalimumab for the treatment of hidradenitis suppurativa.

[No authors listed]

Ann Intern Med. 2012 Dec 18;157(12):I-50. doi: 10.7326/0003-4819-157-12-201212180-00001. No abstract available.

PMID:
23247950
8.

A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa.

Sotiriou E, Goussi C, Lallas A, Chovarda E, Apalla Z, Lazaridou E, Ioannides D.

J Drugs Dermatol. 2012 May;11(5 Suppl):s15-20.

PMID:
22644772
9.

Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.

Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R, Unnebrink K, Gupta SR, Valdecantos WC, Bagel J.

Arch Dermatol. 2011 Apr;147(4):429-36. doi: 10.1001/archdermatol.2010.384. Epub 2010 Dec 20.

PMID:
21173304
10.

Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics.

Sandborn WJ, Colombel JF, Schreiber S, Plevy SE, Pollack PF, Robinson AM, Chao J, Mulani P.

Inflamm Bowel Dis. 2011 Jan;17(1):141-51. doi: 10.1002/ibd.21328.

PMID:
20848500
11.

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF.

Gastroenterology. 2007 Jan;132(1):52-65. Epub 2006 Nov 29.

PMID:
17241859
12.

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.

Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF.

Ann Intern Med. 2007 Jun 19;146(12):829-38. Epub 2007 Apr 30.

PMID:
17470824
13.

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.

Clin Ther. 2003 Jun;25(6):1700-21.

PMID:
12860493
15.

A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa.

Amano M, Grant A, Kerdel FA.

Int J Dermatol. 2010 Aug;49(8):950-5. doi: 10.1111/j.1365-4632.2010.04545.x.

PMID:
21128923
16.

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease.

Panaccione R, Colombel JF, Sandborn WJ, Rutgeerts P, D'Haens GR, Robinson AM, Chao J, Mulani PM, Pollack PF.

Aliment Pharmacol Ther. 2010 Jun;31(12):1296-309. doi: 10.1111/j.1365-2036.2010.04304.x. Epub 2010 Mar 18.

PMID:
20298496
17.

Long-term successful adalimumab therapy in severe hidradenitis suppurativa.

Blanco R, Martínez-Taboada VM, Villa I, González-Vela MC, Fernández-Llaca H, Agudo M, González-López MA.

Arch Dermatol. 2009 May;145(5):580-4. doi: 10.1001/archdermatol.2009.49.

PMID:
19451504
19.

Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.

Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.

Am J Clin Dermatol. 2011 Feb 1;12(1):51-62. doi: 10.2165/11530640-000000000-00000.

PMID:
21110526
20.

Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.

Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P.

Am J Gastroenterol. 2008 Dec;103(12):3132-41. doi: 10.1111/j.1572-0241.2008.02175.x. Epub 2008 Oct 3. Erratum in: Am J Gastroenterol. 2009 Jul;104(7):1894.

PMID:
18853973
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk